NCT06967610View on ClinicalTrials.gov

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

June 1, 2031

Study Completion Date

June 1, 2033

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia (SLL)
Interventions
DRUG

Pirtobrutinib

Given PO 200mg daily

DRUG

Venetoclax

Given PO daily

DRUG

Obinutuzumab

Given IV 100mg day 1, 900 mg day 2, 100mg days 8, 15

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06967610 - Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). | Biotech Hunter | Biotech Hunter